Profile - To The Moon

VincentYeo

Posts · 139Posts · 139
Following · 0Following · 0
Followers · 0Followers · 0

- VincentYeoVincentYeo
  ·2022-02-04
  Comment
  The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
  Here's a roundup of top developments in the biotech space over the last 24 hours.
  The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
  247 Comment
  1
  Share
  Report
- VincentYeoVincentYeo
  ·2021-08-05
  Safe
  Sorry, this post has been deleted
  444 1
  7
  Share
  Report
- VincentYeoVincentYeo
  ·2021-08-03
  Steady as she goes
  122 Comment
  1
  Share
  Report
- VincentYeoVincentYeo
  ·2021-07-27
  Higher please
  333 Comment
  2
  Share
  Report
- VincentYeoVincentYeo
  ·2021-07-27
  $Lithium Americas Corp.(LAC)$ not enough
  360 Comment
  4
  Share
  Report
- VincentYeoVincentYeo
  ·2021-07-23
  O.O--------
  274 Comment
  1
  Share
  Report
- VincentYeoVincentYeo
  ·2021-07-23
  $Westwater Resources Inc(WWR)$o.O
  189 Comment
  2
  Share
  Report
- VincentYeoVincentYeo
  ·2021-07-22
  Soon zoom
  177 Comment
  1
  Share
  Report
- VincentYeoVincentYeo
  ·2021-07-22
  $Cheetah Mobile(CMCM)$ no no no no no
  386 Comment
  Like
  Share
  Report
- VincentYeoVincentYeo
  ·2021-07-21
  Bobibobi
  177 Comment
  1
  Share
  Report
No following yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3571782327892977","uuid":"3571782327892977","gmtCreate":1608688854438,"gmtModify":1706620738076,"name":"VincentYeo","pinyin":"vincentyeo","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","hatId":"ca_profile_frame_DWr5S1","hatName":"","vip":1,"status":2,"fanSize":9,"headSize":2,"tweetSize":139,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.27%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.42%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9098070344,"gmtCreate":1643985441338,"gmtModify":1676533878751,"author":{"id":"3571782327892977","authorId":"3571782327892977","name":"VincentYeo","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571782327892977","authorIdStr":"3571782327892977"},"themes":[],"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098070344","repostId":"2208699317","repostType":2,"repost":{"id":"2208699317","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1643981646,"share":"https://ttm.financial/m/news/2208699317?lang=&edition=fundamental","pubTime":"2022-02-04 21:34","market":"us","language":"en","title":"The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures","url":"https://stock-news.laohu8.com/highlight/detail?id=2208699317","media":"Benzinga","summary":"Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.","content":"<html><body><p>Here's a roundup of top developments in the biotech space over the last 24 hours.</p>\n<h3>Stocks In Focus</h3>\n<h3>Valneva, Pfizer Announces Mid-Stage Results For Lyme Disease Vaccine Candidate</h3>\n<p><strong><a href=\"https://laohu8.com/S/VNVLF\">Valneva SE</a> </strong>(NASDAQ:VALN) and <strong>Pfizer, Inc. </strong>(NYSE:PFE) announced further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with a three-dose primary series vaccination schedule in a planned Phase 3 clinical trial. The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in 2022, subject to regulatory approval.</p>\n<h3>UNITY Biotech Announces Restructuring Including 50% Job Cuts and Halting Earlier-Stage Program</h3>\n<p><strong>UNITY Biotechnology, Inc. </strong>(NASDAQ:UBX) announced it has initiated a restructuring program to align its resources on later-stage programs in ophthalmology while further extending operating capital into the first quarter of 2023.</p>\n<p>All the other programs will be paused. The company also said it will reduce its workforce, primarily in Discovery Research, by about 50%, reducing staff to 34 full-time employees by the middle of the year.</p>\n<p>The stock was up 8.49% at $1.15 in premarket trading.</p>\n<p><em>Click  here  to access Benzinga's FDA Calendar</em></p>\n<h3>Syndax Announces Promotion Of COO Michael Metzger To Role Of CEO</h3>\n<p><strong><a href=\"https://laohu8.com/S/SNDX\">Syndax Pharmaceuticals, Inc. </a></strong>(NASDAQ:SNDX) announced that Michael Metzger, President and Chief Operating Officer, will transition to the role of Chief Executive Officer, effective Thursday. Briggs Morrison, CEO, will transition to the role of President, Head of R&amp;D.</p>\n<h3>Galapagos Says Biotech Investment Firm EcoR1 Holds 5.2% Stake In The Company</h3>\n<p><strong><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> </strong>(NASDAQ:GLPG) noted that EcoR1 Capital held 3.4 million of the company's voting rights, consisting of 211,622 ordinary shares and 3.2 million ADRs. This represents 5.2% of Galapagos' outstanding shares.</p>\n<p>The stock was rising 1.81% to $65.26 in premarket trading.</p>\n<h3>Insider Transactions</h3>\n<p>Shares of COVID-19 testing company <strong>OraSure Technologies, Inc. </strong>(NASDAQ:OSUR) came under pressure after a series of filings with the SEC showed insider transactions.</p>\n<p>The stock was shedding 6.22% to $8.44 in after-hours trading.</p>\n<p><strong><a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a>, Inc.'s</strong>(NASDAQ:AKRO) President and CEO Andrew Cheng sold 10,000 shares in the company that were acquired by exercising of options.</p>\n<p>In premarket trading, the stock was dropping 5.12% to $16.50.</p>\n<p><em>Related Link: Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates </em></p>\n<h3>Earnings</h3>\n<p><strong><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> </strong>(NYSE:SNY) said  its fourth-quarter sales rose 4.1% and business EPS increased 9.8% at constant exchange range. The results were ahead of the expectations of most analysts. The company said it still expects Phase 3 trials of its partnered COVID-19 vaccine to be completed in the first quarter.</p>\n<p><strong><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>, Inc.'s </strong>(NASDAQ:REGN) fourth-quarter revenues jumped 104% to $4.95 billion and non-GAAP EPS came in at $23.72.The results were ahead of expectations.</p>\n<p><strong>Bristol-Myers Squibb Company </strong>(NYSE:BMY) said its fourth-quarter revenues climbed 8% to $11.99 billion and non-GAAP EPS increased from $1.46 to $1.83. The revenues were shy of estimates, while the bottom-line exceeded expectations. The company expects 2022 non-GAAP EPS of $7.65-$7.95 and worldwide revenues of about $47 billion. Analysts, on average, estimate non-GAAP EPS of $7.86 on revenues of $47.12 billion. The company also reaffirmed its long-term targets.</p>\n<p>Among the others that released earnings before the market are <strong>IRadimed Corporation </strong>(NASDAQ:IRMD), <strong>Meridian Bioscience, Inc. </strong>(NASDAQ:VIVO), <strong><a href=\"https://laohu8.com/S/IMVTU\">Immunovant, Inc.</a> </strong>(NASDAQ:IMVT) and<strong>Twist Bioscience Corporation </strong>(NASDAQ:TWST).</p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-02-04 21:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Here's a roundup of top developments in the biotech space over the last 24 hours.</p>\n<h3>Stocks In Focus</h3>\n<h3>Valneva, Pfizer Announces Mid-Stage Results For Lyme Disease Vaccine Candidate</h3>\n<p><strong><a href=\"https://laohu8.com/S/VNVLF\">Valneva SE</a> </strong>(NASDAQ:VALN) and <strong>Pfizer, Inc. </strong>(NYSE:PFE) announced further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with a three-dose primary series vaccination schedule in a planned Phase 3 clinical trial. The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in 2022, subject to regulatory approval.</p>\n<h3>UNITY Biotech Announces Restructuring Including 50% Job Cuts and Halting Earlier-Stage Program</h3>\n<p><strong>UNITY Biotechnology, Inc. </strong>(NASDAQ:UBX) announced it has initiated a restructuring program to align its resources on later-stage programs in ophthalmology while further extending operating capital into the first quarter of 2023.</p>\n<p>All the other programs will be paused. The company also said it will reduce its workforce, primarily in Discovery Research, by about 50%, reducing staff to 34 full-time employees by the middle of the year.</p>\n<p>The stock was up 8.49% at $1.15 in premarket trading.</p>\n<p><em>Click  here  to access Benzinga's FDA Calendar</em></p>\n<h3>Syndax Announces Promotion Of COO Michael Metzger To Role Of CEO</h3>\n<p><strong><a href=\"https://laohu8.com/S/SNDX\">Syndax Pharmaceuticals, Inc. </a></strong>(NASDAQ:SNDX) announced that Michael Metzger, President and Chief Operating Officer, will transition to the role of Chief Executive Officer, effective Thursday. Briggs Morrison, CEO, will transition to the role of President, Head of R&amp;D.</p>\n<h3>Galapagos Says Biotech Investment Firm EcoR1 Holds 5.2% Stake In The Company</h3>\n<p><strong><a href=\"https://laohu8.com/S/GLPG\">Galapagos NV</a> </strong>(NASDAQ:GLPG) noted that EcoR1 Capital held 3.4 million of the company's voting rights, consisting of 211,622 ordinary shares and 3.2 million ADRs. This represents 5.2% of Galapagos' outstanding shares.</p>\n<p>The stock was rising 1.81% to $65.26 in premarket trading.</p>\n<h3>Insider Transactions</h3>\n<p>Shares of COVID-19 testing company <strong>OraSure Technologies, Inc. </strong>(NASDAQ:OSUR) came under pressure after a series of filings with the SEC showed insider transactions.</p>\n<p>The stock was shedding 6.22% to $8.44 in after-hours trading.</p>\n<p><strong><a href=\"https://laohu8.com/S/AKRO\">Akero Therapeutics</a>, Inc.'s</strong>(NASDAQ:AKRO) President and CEO Andrew Cheng sold 10,000 shares in the company that were acquired by exercising of options.</p>\n<p>In premarket trading, the stock was dropping 5.12% to $16.50.</p>\n<p><em>Related Link: Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates </em></p>\n<h3>Earnings</h3>\n<p><strong><a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> </strong>(NYSE:SNY) said  its fourth-quarter sales rose 4.1% and business EPS increased 9.8% at constant exchange range. The results were ahead of the expectations of most analysts. The company said it still expects Phase 3 trials of its partnered COVID-19 vaccine to be completed in the first quarter.</p>\n<p><strong><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a>, Inc.'s </strong>(NASDAQ:REGN) fourth-quarter revenues jumped 104% to $4.95 billion and non-GAAP EPS came in at $23.72.The results were ahead of expectations.</p>\n<p><strong>Bristol-Myers Squibb Company </strong>(NYSE:BMY) said its fourth-quarter revenues climbed 8% to $11.99 billion and non-GAAP EPS increased from $1.46 to $1.83. The revenues were shy of estimates, while the bottom-line exceeded expectations. The company expects 2022 non-GAAP EPS of $7.65-$7.95 and worldwide revenues of about $47 billion. Analysts, on average, estimate non-GAAP EPS of $7.86 on revenues of $47.12 billion. The company also reaffirmed its long-term targets.</p>\n<p>Among the others that released earnings before the market are <strong>IRadimed Corporation </strong>(NASDAQ:IRMD), <strong>Meridian Bioscience, Inc. </strong>(NASDAQ:VIVO), <strong><a href=\"https://laohu8.com/S/IMVTU\">Immunovant, Inc.</a> </strong>(NASDAQ:IMVT) and<strong>Twist Bioscience Corporation </strong>(NASDAQ:TWST).</p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IMVT":"Immunovant, Inc.","TWST":"Twist Bioscience Corp","SNDX":"Syndax Pharmaceuticals, Inc. ","VIVO":"美鼎生物","UBX":"Unity Biotechnology","SNY":"赛诺菲安万特","GLPG":"Galapagos NV","SNYNF":"Sanofi","VALN":"Valneva SE","IRMD":"iRadimed Corporation","REGN":"再生元制药公司","PFE":"辉瑞","IBB":"生物科技指数ETF-iShares Nasdaq","BMY":"施贵宝","UNTY":"联合银行","AKRO":"Akero Therapeutics","OSUR":"奥瑞许科技"},"source_url":"https://www.benzinga.com/general/biotech/22/02/25418129/the-daily-biotech-pulse-sanofi-bristol-myers-squibb-gain-on-earnings-valneva-pfizer-tout-positive","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208699317","content_text":"Here's a roundup of top developments in the biotech space over the last 24 hours.\nStocks In Focus\nValneva, Pfizer Announces Mid-Stage Results For Lyme Disease Vaccine Candidate\nValneva SE (NASDAQ:VALN) and Pfizer, Inc. (NYSE:PFE) announced further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with a three-dose primary series vaccination schedule in a planned Phase 3 clinical trial. The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in 2022, subject to regulatory approval.\nUNITY Biotech Announces Restructuring Including 50% Job Cuts and Halting Earlier-Stage Program\nUNITY Biotechnology, Inc. (NASDAQ:UBX) announced it has initiated a restructuring program to align its resources on later-stage programs in ophthalmology while further extending operating capital into the first quarter of 2023.\nAll the other programs will be paused. The company also said it will reduce its workforce, primarily in Discovery Research, by about 50%, reducing staff to 34 full-time employees by the middle of the year.\nThe stock was up 8.49% at $1.15 in premarket trading.\nClick  here  to access Benzinga's FDA Calendar\nSyndax Announces Promotion Of COO Michael Metzger To Role Of CEO\nSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced that Michael Metzger, President and Chief Operating Officer, will transition to the role of Chief Executive Officer, effective Thursday. Briggs Morrison, CEO, will transition to the role of President, Head of R&D.\nGalapagos Says Biotech Investment Firm EcoR1 Holds 5.2% Stake In The Company\nGalapagos NV (NASDAQ:GLPG) noted that EcoR1 Capital held 3.4 million of the company's voting rights, consisting of 211,622 ordinary shares and 3.2 million ADRs. This represents 5.2% of Galapagos' outstanding shares.\nThe stock was rising 1.81% to $65.26 in premarket trading.\nInsider Transactions\nShares of COVID-19 testing company OraSure Technologies, Inc. (NASDAQ:OSUR) came under pressure after a series of filings with the SEC showed insider transactions.\nThe stock was shedding 6.22% to $8.44 in after-hours trading.\nAkero Therapeutics, Inc.'s(NASDAQ:AKRO) President and CEO Andrew Cheng sold 10,000 shares in the company that were acquired by exercising of options.\nIn premarket trading, the stock was dropping 5.12% to $16.50.\nRelated Link: Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates \nEarnings\nSanofi (NYSE:SNY) said  its fourth-quarter sales rose 4.1% and business EPS increased 9.8% at constant exchange range. The results were ahead of the expectations of most analysts. The company said it still expects Phase 3 trials of its partnered COVID-19 vaccine to be completed in the first quarter.\nRegeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) fourth-quarter revenues jumped 104% to $4.95 billion and non-GAAP EPS came in at $23.72.The results were ahead of expectations.\nBristol-Myers Squibb Company (NYSE:BMY) said its fourth-quarter revenues climbed 8% to $11.99 billion and non-GAAP EPS increased from $1.46 to $1.83. The revenues were shy of estimates, while the bottom-line exceeded expectations. The company expects 2022 non-GAAP EPS of $7.65-$7.95 and worldwide revenues of about $47 billion. Analysts, on average, estimate non-GAAP EPS of $7.86 on revenues of $47.12 billion. The company also reaffirmed its long-term targets.\nAmong the others that released earnings before the market are IRadimed Corporation (NASDAQ:IRMD), Meridian Bioscience, Inc. (NASDAQ:VIVO), Immunovant, Inc. (NASDAQ:IMVT) andTwist Bioscience Corporation (NASDAQ:TWST).","news_type":1},"isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890600844,"gmtCreate":1628097890988,"gmtModify":1703501237198,"author":{"id":"3571782327892977","authorId":"3571782327892977","name":"VincentYeo","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571782327892977","authorIdStr":"3571782327892977"},"themes":[],"htmlText":"Safe","listText":"Safe","text":"Safe","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/890600844","repostId":"1187165636","repostType":4,"isVote":1,"tweetType":1,"viewCount":444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":807189471,"gmtCreate":1628005911593,"gmtModify":1703499584443,"author":{"id":"3571782327892977","authorId":"3571782327892977","name":"VincentYeo","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571782327892977","authorIdStr":"3571782327892977"},"themes":[],"htmlText":"Steady as she goes","listText":"Steady as she goes","text":"Steady as she goes","images":[{"img":"https://static.tigerbbs.com/55d5bcd1bab2a06f473bc0e2f6b40932","width":"1440","height":"3135"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807189471","isVote":1,"tweetType":1,"viewCount":122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":800719756,"gmtCreate":1627318431875,"gmtModify":1703487593424,"author":{"id":"3571782327892977","authorId":"3571782327892977","name":"VincentYeo","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571782327892977","authorIdStr":"3571782327892977"},"themes":[],"htmlText":"Higher please","listText":"Higher please","text":"Higher please","images":[{"img":"https://static.tigerbbs.com/58b8e415505aa87496ca550c45a85c8f","width":"1440","height":"4461"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/800719756","isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":800719456,"gmtCreate":1627318412375,"gmtModify":1703487592759,"author":{"id":"3571782327892977","authorId":"3571782327892977","name":"VincentYeo","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571782327892977","authorIdStr":"3571782327892977"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LAC\">$Lithium Americas Corp.(LAC)$</a> not enough","listText":"<a href=\"https://laohu8.com/S/LAC\">$Lithium Americas Corp.(LAC)$</a> not enough","text":"$Lithium Americas Corp.(LAC)$ not enough","images":[{"img":"https://static.tigerbbs.com/226c6ef167f77784c755be9a7b8f6e2a","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/800719456","isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":175487935,"gmtCreate":1627047004327,"gmtModify":1703483193720,"author":{"id":"3571782327892977","authorId":"3571782327892977","name":"VincentYeo","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571782327892977","authorIdStr":"3571782327892977"},"themes":[],"htmlText":"O.O--------","listText":"O.O--------","text":"O.O--------","images":[{"img":"https://static.tigerbbs.com/dc4eb86a368d66a7a30735fd83c21514","width":"1440","height":"4585"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/175487935","isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":175484988,"gmtCreate":1627046960244,"gmtModify":1703483191734,"author":{"id":"3571782327892977","authorId":"3571782327892977","name":"VincentYeo","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571782327892977","authorIdStr":"3571782327892977"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/WWR\">$Westwater Resources Inc(WWR)$</a>o.O","listText":"<a href=\"https://laohu8.com/S/WWR\">$Westwater Resources Inc(WWR)$</a>o.O","text":"$Westwater Resources Inc(WWR)$o.O","images":[{"img":"https://static.tigerbbs.com/63a3723094b401ddc9c4838673d38377","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/175484988","isVote":1,"tweetType":1,"viewCount":189,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":172109943,"gmtCreate":1626941469182,"gmtModify":1703480979651,"author":{"id":"3571782327892977","authorId":"3571782327892977","name":"VincentYeo","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571782327892977","authorIdStr":"3571782327892977"},"themes":[],"htmlText":"Soon zoom","listText":"Soon zoom","text":"Soon zoom","images":[{"img":"https://static.tigerbbs.com/c6520f51485e72803434472b3b2ccf8b","width":"1440","height":"4744"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172109943","isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":172100491,"gmtCreate":1626941450413,"gmtModify":1703480979324,"author":{"id":"3571782327892977","authorId":"3571782327892977","name":"VincentYeo","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571782327892977","authorIdStr":"3571782327892977"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CMCM\">$Cheetah Mobile(CMCM)$</a> no no no no no","listText":"<a href=\"https://laohu8.com/S/CMCM\">$Cheetah Mobile(CMCM)$</a> no no no no no","text":"$Cheetah Mobile(CMCM)$ no no no no no","images":[{"img":"https://static.tigerbbs.com/f4a191706105c0172bf7bd6bbd7d193f","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172100491","isVote":1,"tweetType":1,"viewCount":386,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":176112210,"gmtCreate":1626871134730,"gmtModify":1703479604185,"author":{"id":"3571782327892977","authorId":"3571782327892977","name":"VincentYeo","avatar":"https://static.tigerbbs.com/304c3897d2ddafdd707517fbd4c7a86d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571782327892977","authorIdStr":"3571782327892977"},"themes":[],"htmlText":"Bobibobi","listText":"Bobibobi","text":"Bobibobi","images":[{"img":"https://static.tigerbbs.com/8ce1d0a1044464fa5c3efc7e12adb389","width":"1440","height":"4585"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176112210","isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}